GlassScriptPhysician profile
Benjamin Willett
NPI 1467722066
$10,543.76
in general payments reported to CMS, 2019-2025
33 companies · $7,761 in 2025
The $7,761 reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.00 · 2022: $206 · 2023: $531 · 2024: $2,033 · 2025: $7,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,716 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,352 · Consulting Fee: $2,016 · Education: $144 · Travel and Lodging: $96.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,715.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,352.00 |
| Consulting Fee | $2,016.00 |
| Education | $143.80 |
| Travel and Lodging | $96.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,353.05 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,835.87 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $710.39 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $587.19 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $290.85 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $279.15 | 2023-2025 | Glassia, Hyqvia, Cuvitru |
| Merck Sharp & Dohme LLC | $272.19 | 2024-2025 | Zerbaxa, Winrevair, Keytruda |
| United Therapeutics Corporation | $240.64 | 2024-2025 | Tyvaso, Orenitram, Remodulin |
| Abbvie INC. | $233.23 | 2024 | |
| Insmed, INC. | $200.22 | 2024-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $183.85 | 2024-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $140.98 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $130.58 | 2025 | Terlivaz, Acthar |
| Incyte Corporation | $123.44 | 2023-2024 | Opzelura |
| Pfizer INC. | $105.66 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $98.99 | 2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $94.65 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $87.54 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $83.93 | 2024-2025 | Uptravi, Opsumit |
| Baxter Healthcare | $80.29 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.98 | 2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $56.05 | 2024-2025 | |
| Optinose US, INC. | $47.96 | 2022-2024 | |
| Kaleo, INC. | $40.98 | 2023-2024 | Auvi-Q |
| Viatris Specialty LLC | $30.32 | 2025 | Yupelri |
| Blueprint Medicines Corporation | $26.54 | 2023 | Ayvakit |
| Csl Behring | $24.62 | 2024 | Haegarda |
| Pharming Healthcare, INC. | $24.19 | 2025 | Ruconest |
| Biocryst US Sales Co., LLC | $20.35 | 2024 | Orladeyo |
| Inspire Medical Systems, INC. | $18.44 | 2025 | Inspire |
| Octapharma USA, INC. | $17.90 | 2024 | Panzyga |
| Bayer Healthcare Pharmaceuticals INC. | $17.01 | 2025 | |
| Axsome Therapeutics, INC. | $14.73 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Willett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.